WO2007108272A1 - 癌治療用キットおよび癌治療用医薬組成物 - Google Patents
癌治療用キットおよび癌治療用医薬組成物 Download PDFInfo
- Publication number
- WO2007108272A1 WO2007108272A1 PCT/JP2007/053326 JP2007053326W WO2007108272A1 WO 2007108272 A1 WO2007108272 A1 WO 2007108272A1 JP 2007053326 W JP2007053326 W JP 2007053326W WO 2007108272 A1 WO2007108272 A1 WO 2007108272A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- chemotherapeutic agent
- cancer treatment
- kit
- cancer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000011275 oncology therapy Methods 0.000 title abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 84
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 59
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 59
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 230000012010 growth Effects 0.000 claims abstract description 17
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 7
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 150000007522 mineralic acids Chemical class 0.000 claims description 19
- 150000007524 organic acids Chemical class 0.000 claims description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 14
- 229960002949 fluorouracil Drugs 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- 229960004679 doxorubicin Drugs 0.000 claims description 9
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 9
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- -1 fluorodeuridine Chemical compound 0.000 claims description 6
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- 230000007067 DNA methylation Effects 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 229960002756 azacitidine Drugs 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 239000000051 antiandrogen Substances 0.000 claims description 4
- 239000013059 antihormonal agent Substances 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 239000000328 estrogen antagonist Substances 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 4
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 4
- 229960003087 tioguanine Drugs 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- 102000015790 Asparaginase Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 3
- 229960003272 asparaginase Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 230000010721 Tubulin Interactions Effects 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 229960000473 altretamine Drugs 0.000 claims 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 4
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 64
- 230000002195 synergetic effect Effects 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 29
- 230000009036 growth inhibition Effects 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 208000034578 Multiple myelomas Diseases 0.000 description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 14
- 230000000996 additive effect Effects 0.000 description 10
- 238000011580 nude mouse model Methods 0.000 description 9
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 7
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 229960000604 valproic acid Drugs 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229940063683 taxotere Drugs 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- GCPXMJHSNVMWNM-UHFFFAOYSA-N arsenous acid Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NPTTZSYLTYJCPR-MZJVJLTCSA-N (2r,4s)-2,3,4-trihydroxypentanedioic acid Chemical compound OC(=O)[C@@H](O)C(O)[C@@H](O)C(O)=O NPTTZSYLTYJCPR-MZJVJLTCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Cancer treatment kit and pharmaceutical composition for cancer treatment are Cancer treatment kit and pharmaceutical composition for cancer treatment
- the present invention relates to a kit for inhibiting tumor and cancer growth in mammals, and more particularly, for cancer therapy for inhibiting cancer and tumor growth in mammals, particularly humans and warm-blooded animals.
- the present invention relates to a kit and a pharmaceutical composition for treating cancer.
- Cancer is the leading cause of death in animals and humans.
- many of these drugs have the problem of destroying normal cells. It was.
- today's main treatments are with surgery, radiation therapy, and chemotherapeutic agents.
- Chemotherapeutic approaches are said to work well for metastatic cancers or particularly advanced cancers.
- the exact mechanism of action of these chemotherapeutic agents is not always known.
- some chemotherapeutic agents significantly reduce tumor mass after treatment, unfortunately they cannot often be administered to the same patient when the cancer recurs.
- chemotherapeutic agents generally have a narrow range between the effective dose and the maximum tolerated dose, so careful attention must be paid to the dose.
- Non-Patent Document 1 retinoids are involved in the signal transduction system of immune cells and cause various immune responses. Recently, retinoids have recently suppressed Thl expression of T cells and enhanced Th2 expression. Has been reported! (Non-Patent Document 1).
- Non-patent Document 2 Non-patent Document 2
- Non-patent literature 1 M.Iwata, et al. Retinoic acids exerts direct effects on T cells to suppre ss Thl development and enhance Th2 development via retinoic acid receptors. Inter national Immunology 15 (8), pp. 1017-1025, 2003
- Non-Patent Document 2 Sengupta, S. et al. Temporal atrgeting of tumor cells and neovasculat ure with a nanoscale delivery system.Nature 436, pp. 568-572,2005 Disclosure of the Invention
- retinoids cause various immune responses to increase specificity for tumor cells, and the combination of drugs that target tumor blood vessels and chemotherapeutic agents targets tumor cells. It is expected to be highly effective and reduce toxicity to normal cells. On the other hand, there is a strong demand for an administration means that does not act on normal cells and that enhances cytotoxicity to tumor cells.
- an object of the present invention is to provide a cancer treatment kit and a cancer treatment pharmaceutical composition for inhibiting tumor and cancer growth in mammals more than ever. Means for solving the problem
- the present invention relates to the following (1) to (12).
- a kit for cancer treatment comprising a combination of two drugs in a kit form, wherein the first drug comprises a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof,
- the second medicine is a cancer treatment kit characterized by containing a chemotherapeutic agent for cancer treatment.
- the synthetic retinoid is an retinoic acid receptor (RAR ⁇ , j8, ⁇ ) or retinoid receptor (RXR ⁇ , ⁇ , ⁇ ) agonist
- RAR ⁇ , j8, ⁇ retinoic acid receptor
- RXR ⁇ , ⁇ , ⁇ retinoid receptor
- it is a kit for treating cancer, which is an antagonist or a pharmaceutically acceptable organic or inorganic acid addition salt thereof.
- the first medicament is 0.5 to 30 mg of a synthetic retinoid or a pharmaceutically acceptable organic thereof per human or animal.
- a kit for cancer treatment comprising an inorganic acid addition salt, wherein the second medicament comprises 1.0 to L000 mg of chemotherapeutic agent per human or animal.
- the chemotherapeutic agent is a DNA interacting agent, a metabolite, a tubulin interacting agent, an anticancer antibiotic, an enzyme inhibitor A cancer treatment kit selected from the group consisting of a growth-promoting signal inhibitor and an anti-hormonal agent.
- the chemotherapeutic agent is selected from steroids, asparaginase, hydroxyurea, cisplatin, cyclophosphamide, artretamine, bleomycin, dactinomycin, doxorubicin, etoposide, and teposide. It is a kit for cancer treatment in which group power is also selected.
- the chemotherapeutic agent also has methotrexate, fluorouracil, fluorodeoxyuridine, azacitidine, cytarabine, mercaptopurine, 6-thioguanine, pentostatin, and fludarabine.
- methotrexate fluorouracil
- fluorodeoxyuridine azacitidine
- cytarabine mercaptopurine
- 6-thioguanine 6-thioguanine
- pentostatin pentostatin
- fludarabine fludarabine
- the chemotherapeutic agent is a cancer treatment kit in which a group power consisting of a vinca alkaloid and a taxane is selected.
- the chemotherapeutic agent is a growth factor receptor tyrosine kinase inhibitor, cycloxygenase-2 inhibitor, histone deacetylase inhibitor, and DNA methylation inhibition. It is a kit for cancer treatment in which group power consisting of agents is also selected.
- chemotherapeutic agent is a steroid agent, an anti-estrogen agent, or an anti-androgen agent.
- the first medicine is a synthetic retinoid or a pharmaceutically acceptable dose thereof for 1 to 21 days or 28 days Containing an organic or organic acid addition salt and the second medicament is for therapeutic use for 21 days or 28 days per day.
- a cancer treatment kit comprising an amount of a chemotherapeutic agent.
- the chemotherapeutic agent exhibiting cytotoxicity further reduces or reduces the bulk of the tumor mass. be able to. It is also useful to administer a synthetic retinoid and a chemotherapeutic agent simultaneously.
- Cancers to be treated according to the present invention include blood cancer such as acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, non-Hodgkin lymphoma, lung cancer, colon cancer, stomach cancer, liver cancer, spleen cancer, bile duct cancer Gastrointestinal cancer such as breast cancer, prostate cancer, ovarian cancer and uterine cancer.
- 2 is a graph showing a synergistic effect of growth inhibition by 2 3.
- FIG. 2 is a graph showing the synergistic effect of the growth inhibitory action of TM-411 combined with 5-AZ in human acute promyelocytic leukemia cell line HL-60.
- FIG. 3 is a graph showing the additive effect and synergistic effect of the growth inhibition effect of TM-411 combined with Mel in human multiple myeloma cell line RPMI8226.
- FIG. 4 is a graph showing the synergistic effect of the growth inhibitory effect of the combined use of TM-411 and PSL on human multiple myeloma cell line RPMI8226.
- FIG. 5 is a graph showing the synergistic effect of the growth inhibitory effect of the combined use of TM-411 and DEX on human multiple myeloma cell line RPMI8226.
- FIG. 6 is a graph showing the synergistic effect of the growth inhibitory effect of the combined use of TM-411 and 5-AZ on human multiple myeloma cell line RPMI8226.
- FIG. 7 is a graph showing the additive effect and synergistic effect for growth suppression by the combined use of TM-411 and VPA in human hepatocellular carcinoma cell HH-7.
- the synthetic retinoid contained in the first medicament or a pharmacological agent thereof Preferred examples of the organic or inorganic acid addition salt acceptable for benzoic acid include a benzoic acid derivative or a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and particularly preferably the following formula ( 1),
- Synthetic retinoid is retinoic acid receptor (RAR ⁇ , j8, ⁇ ) or retinoid receptor (RXR ⁇ , ⁇ , ⁇ ) agonist or antagonist, or pharmaceutically acceptable Possible organic or inorganic acid addition salts.
- the DNA interaction agent of the chemotherapeutic agent contained in the second medicament includes the alkylating agents cyclophosphamide, isofamide, melphalan, tiotepa, busulfan, carmustine, Examples include oral mucin, cisplatin, carboplatin and the like.
- Examples of the DNA topoisomerase I inhibitor include camptothecin
- examples of the DNA topoisomerase II inhibitor include etoposide, theposide, daunorubicin, doxorubicin, and mitoxantrone.
- Preferred examples include DNA interacting agents that can be administered orally, cyclophosphamide, melphalan, cisplatin, camptothecin, etoposide, and doxorubicin.
- a chemotherapeutic agent As an antimetabolite of a chemotherapeutic agent, one inhibits DNA replication by inhibiting biosynthesis of deoxyribonucleoside triphosphate, which is a direct precursor of DNA synthesis. Some are also sufficiently similar to purines or pyrimidines and can be substituted for them in the anabolic nucleotide pathways. These analogs can then be substituted into DNA and RNA in place of their normal counterparts.
- Useful antimetabolites here include folic acid antagonists such as methotrexate and trimetrexate and pyrimidine antagonists such as 5-fluorouracil, fluorodeoxyuridine, azacitidine ( Azacitidine), cytarabine and floc
- pyrimidine antagonists such as 5-fluorouracil, fluorodeoxyuridine, azacitidine ( Azacitidine), cytarabine and floc
- the purine antagonists include mercaptopurine, 6-thioguanine, fludarabine, and pentostatin.
- Examples of the ribonutaletide reductase inhibitor include hydroxyurea.
- Preferable examples include methotrexate, 5-fluorouracil, cytarabine, and fludarabine, which can be administered orally.
- DNA methylation inhibitor include 5-aza-2′-deoxycytidine (hereinafter abbreviated as “5-AZ”).
- the tubulin-interacting agent of the chemotherapeutic agent includes tubulin, that is, it acts by binding to a specific site on a protein that is polymerized to form a microtubule of the cell. It is done.
- tubulin that is, it acts by binding to a specific site on a protein that is polymerized to form a microtubule of the cell. It is done.
- paclitaxel and docetaxel that can be administered orally are mentioned.
- Anticancer antibiotics for chemotherapeutic agents include bleomycin, which exhibits a DNA-cleaving action, mitomycin, a bioreductive alkylating agent, and doxorubicin, a DNA intercalating agent.
- doxorubicin is used.
- anti-cancer antibiotics used as chemotherapeutic agents include valproic acid, which is used as an antiepileptic agent, and arsenous acid, which inhibits mitochondrial membrane permeability.
- Enzyme inhibitors of chemotherapeutic agents include cycloxygenase 2 inhibitor celecoxib, oral fuecoxib, curcumin, etc., histone deacetylase inhibitor valproic acid, FK-228, MS-275, etc. , A farnesyltransferase inhibitor R115777, BMS2 14462, and the like, and a DNA methyl candy inhibitor 5-AZ and the like.
- Preferable examples include celecoxib, valproic acid, FK-228 and 5-AZ, which can be administered orally.
- Growth factor signal inhibitors of chemotherapeutic agents include EGFR tyrosine kinase inhibitors Gefitiv, Erlothib, Bcr-abl tyrosine kinase inhibitor Imatib, and the like.
- gefitinib and imatib which can be administered orally are mentioned.
- Chemotherapeutic luteinizing hormone-releasing hormone agents or gonadotropin-releasing hormone antagonists are primarily used in the treatment of prostate cancer. These are leuprolide acetate (1 euprolideacetate) and goserelin acetate.
- Antihormonal agents include antiestrogens such as tamoxifen, antiandrogens such as flutamide, bicalutamide, and anti-adrenal agents such as mitoten and aminoglutethimide.
- Preferred examples include tamoxifen, flutamide, bicalutamide, and anti-adrenal drugs that can be administered orally.
- Steroids used for hormone therapy include dexamethasone, and hormones or antihormone antagonists include prednisolone.
- the first drug and the second drug in the kit of the present invention are administered by administering an effective amount either orally, rectally, topically, or parenterally, intravenously or intratumorally. Effective in inhibiting the growth of cancer and other tumors in humans or animals.
- Each drug in the powerful unit is solid or gel, such as pills, tablets, capsules, ribosomes, orally, rectally, topically, intravenously or parenterally, or injected into or near the tumor (See Cancer Chemotherapy Handbook 2nd edition, pages 15-34, Appleton & Lange (Connecticut, 1994)).
- the first medicament comprises a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof at a daily dose of 21 days or 28 days.
- the two medicaments comprise a therapeutic dose of a chemotherapeutic agent from 1 to 21 or 28 days.
- the synthetic retinoid when treating with a brute force kit, it can be any suitable amount effective in the treatment of the particular cancer or tumor type being treated, and methods of applying an effective amount include: It also depends on the tumor being treated.
- the synthetic retinoid is administered first to reduce the size of the cancer or tumor mass. This usually takes 2 to 8 weeks. The decrease in tumor or cancer cells is less than 50% of the original level. Then, when tumor shrinkage is observed, a chemotherapeutic agent is administered. Synthetic retinoids are relatively safe and can be administered from 2 weeks to 1 year as needed to maintain their effectiveness in reducing cancer regrowth.
- Tamibarotene (hereinafter simply abbreviated as “TM-411”) was used as the synthetic retinoid. The same applies to the following embodiments.
- TM-411 Tamibarotene
- DXL general name Taxotere
- a 6-week-old BALBZcAJcl-nu nude mouse was transplanted with a human breast cancer Br-10 tumor fragment under the dorsal skin using a trocar needle. Administration was also started when the tumor volume reached 100-300 mm 3 .
- TM-411 was orally administered lmgZkg once for Z days for 28 days.
- DX L was administered intravenously at 7.5 mgZkg three times at 4-day intervals from day 1.
- the TM-411 + DXL combination group was administered with the same dosage and administration method as each single agent.
- the first day of administration was taken as the first day, and the tumor diameter was measured every day until the day after the end of administration (day 29) to examine the presence or absence of growth inhibition.
- the results are shown in Table 1 below.
- physiological saline was administered in the same dosage and administration method as each single agent.
- Tumor volume (mm 3 ) was calculated from the formula of major axis X minor axis 2 Z2.
- TM-411, DXL and TM-411 + DX L were administered to human breast cancer Br-10Z nude mice, TM-411 and DXL were able to significantly suppress tumor growth TM- 411 + The combined use of DXL exceeded the effect of the single agent and showed a synergistic effect.
- TM-411 5-fluorouracil (5-FU for human liver 3 ⁇ 4JHH-7 / nude mice)
- 5-FU 5-fluorouracil
- 5 FUJ Fluorouracil
- a 6-week-old BALB / cAJcl-nu nude mouse was transplanted with a tumor piece of human hepatic HH-7 using a trocar needle under the dorsal skin. Administration was also started when the tumor volume reached 100-300 mm 3 .
- TM-411 was orally administered at a dose of 3mgZkg once for Z days for 20 days.
- 5-FU was orally administered at 15.2 mg / kg for 5 days on the 8th day and every 12th day.
- the TM-411 + 5-FU combination group was administered with the same dosage and administration method as each single agent.
- the first day of administration was the first day, and the tumor diameter was measured every day until the day after the end of administration (day 21) to examine the presence or absence of growth inhibition.
- the results are shown in Table 2 below.
- physiological saline was administered in the same dosage and administration method as each single agent.
- TM-411, 5-FU and TM-411 + 5-FU were administered to human hepatic HH-7Z nude mice, TM-411, 5-FU was able to inhibit tumor growth.
- TM-411 + 5- FU combined exceeded the effect of the single agent and showed a synergistic effect.
- AD R doxorubicin
- the TM-411 + ADR combination group was administered with the same dosage and administration method as each single agent.
- the first day of administration was taken as the first day, and the tumor diameter was measured every day until the end of administration (day 20) to examine the presence or absence of growth inhibition.
- the results are shown in Table 3 below.
- physiological saline was administered by the same dosage and administration method as each single agent.
- TM-411, ADR inhibited tumor growth.
- TM-411 + ADR combination exceeded the effect of single agent and showed a synergistic effect.
- prednisolone (hereinafter abbreviated as “PSL”) manufactured by Shionogi & Co., Ltd. was used.
- mice 7-week-old NODZSCIDZ o / c nuU (NOG) mice were divided into 5 groups of 10 mice (9 mice only for the control group), and 2 x 16 6 multiple myeloma lines U266 cells were placed in the tail vein for all individuals. Transplanted via (day 0). The first group was an untreated control group, 2-411 'lmgZkg was administered orally to the second group, and TM-411'3mgZkg was administered to the third group for 28 days from the first day. Group 4 was orally administered PSL 7.5 mgZkg for 8 days from day 21.
- TM-411 and PSL were administered to human multiple myeloma U266ZNOG mice, TM-411 and PSL decreased the blood HgE concentration.
- TM-411 + PSL combination showed a synergistic effect on the reduction of blood human IgE concentration.
- As O arsenous acid manufactured by Sigma-aldrich Japan
- the horizontal axis represents the concentration of ED in the growth inhibition curve of TM-411 as 1.
- the vertical axis indicates the ED concentration in the As O growth inhibition curve when the ED concentration is 1.
- 5-AZ made by C ALBIOCHEM was used as a DN A methylation inhibitor.
- the horizontal axis represents the ED concentration of 1 in the growth inhibition curve of TM-411.
- the vertical axis represents the ED concentration on the 5-AZ growth inhibition curve, assuming 1
- Ratio On the straight line connecting 1.0 of both axes, an additive effect is shown, and below the straight line, a synergistic effect is shown. As shown in FIG. 2, in human acute promyelocytic leukemia cell line HL-60, the combined use of TM-411 and 5-AZ showed a synergistic effect on the growth inhibitory action.
- Melphalan (hereinafter abbreviated as “Mel”) was used as a chemotherapeutic agent.
- Human multiple myeloma cell line RPMI8226 was cultured in RPMI 1640 medium supplemented with 10% ushi fetal serum, and TM-411 and Mel were added to verify the synergistic effect on the growth inhibitory action.
- the horizontal axis is 1 for the ED concentration in the growth inhibition curve of TM-411.
- the vertical axis represents the ED concentration in Mel's growth inhibition curve, assuming 1
- TM-411 and PSL were added to verify the synergistic effect in the growth inhibitory action.
- the horizontal axis represents ED concentration in the growth inhibition curve of TM-411 as 1.
- the vertical axis shows the ED concentration in the PSL growth inhibition curve when the concentration is 1.
- Dexamethasone (hereinafter abbreviated as “DEX”) was used as a chemotherapeutic agent.
- the horizontal axis is 1 for the concentration of ED in the growth inhibition curve of TM-411.
- the vertical axis represents the ED concentration on the DEX growth inhibition curve when the concentration is 1.
- 5-AZ was used as a methyl candy inhibitor.
- TM-411 and 5-AZ were added to verify the synergistic effect in the growth inhibitory action.
- the horizontal axis represents the ED concentration of 1 in the growth inhibition curve of TM-411.
- the vertical axis represents the ED concentration on the 5-AZ growth inhibition curve, assuming 1
- Valproic acid (hereinafter abbreviated as “VPA”) was used as a chemotherapeutic agent.
- TM-411 and VPA were added to verify the additive synergistic effect in the growth inhibitory action.
- the horizontal axis represents ED concentration in the growth inhibition curve of TM-411 as 1.
- the vertical axis represents the ED concentration in the VAP growth inhibition curve when the concentration is 1.
- Ratio On the straight line connecting 1.0 of both axes, an additive effect is shown, and below the straight line, a synergistic effect is shown. As shown in FIG. 7, in human hepatocellular carcinoma cell HH-7, the combined use of TM-411 and VPA showed a synergistic effect from the phase calo in the growth inhibitory action.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008506203A JP5113038B2 (ja) | 2006-03-23 | 2007-02-22 | 癌治療用キットおよび癌治療用医薬組成物 |
US12/293,912 US20090117203A1 (en) | 2006-03-23 | 2007-02-22 | Kit for cancer treatment and pharmaceutical composition for cancer treatment |
EP07737319A EP2005954B8 (en) | 2006-03-23 | 2007-02-22 | Kit for cancer therapy and pharmaceutical composition for cancer therapy |
ES07737319T ES2395401T3 (es) | 2006-03-23 | 2007-02-22 | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer |
US13/547,758 US20120277295A1 (en) | 2006-03-23 | 2012-07-12 | Kit for cancer treatment and pharmaceutical composition for cancer treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006080691 | 2006-03-23 | ||
JP2006-080691 | 2006-03-23 | ||
JP2007-032777 | 2007-02-13 | ||
JP2007032777 | 2007-02-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/547,758 Division US20120277295A1 (en) | 2006-03-23 | 2012-07-12 | Kit for cancer treatment and pharmaceutical composition for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007108272A1 true WO2007108272A1 (ja) | 2007-09-27 |
Family
ID=38522308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053326 WO2007108272A1 (ja) | 2006-03-23 | 2007-02-22 | 癌治療用キットおよび癌治療用医薬組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090117203A1 (ja) |
EP (2) | EP2404596A1 (ja) |
JP (1) | JP5113038B2 (ja) |
ES (1) | ES2395401T3 (ja) |
WO (1) | WO2007108272A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015178426A1 (ja) * | 2014-05-21 | 2015-11-26 | 国立研究開発法人産業技術総合研究所 | がん幹細胞の増殖抑制剤 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2329817A1 (en) * | 2009-09-04 | 2011-06-08 | Ernst-Moritz-Arndt-Universität Greifswald | Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer |
NZ607547A (en) * | 2010-09-01 | 2015-06-26 | Univ Jefferson | Composition and method for muscle repair and regeneration |
US11077139B2 (en) | 2013-12-30 | 2021-08-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia |
EA028614B1 (ru) | 2014-05-22 | 2017-12-29 | Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" | Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака |
BR122023024813A2 (pt) | 2015-03-31 | 2024-02-20 | Syros Pharmaceuticals, Inc. | Uso de tamibaroteno ou um sal farmaceuticamente aceitável do mesmo, ou de uma composição farmacêutica embalada compreendendo o mesmo, e, composição farmacêutica embalada compreendendo tamibaroteno ou um sal farmaceuticamente aceitável do mesmo |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
IL262156B2 (en) * | 2016-04-08 | 2024-03-01 | Syros Pharmaceuticals Inc | RARA agonists for the treatment of AML and MDS |
JP7332015B2 (ja) | 2018-10-04 | 2023-08-23 | 株式会社大林組 | 建築作業装置および建築作業方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07215882A (ja) * | 1993-09-22 | 1995-08-15 | Univ Leland Stanford Jr | 腫瘍の治療方法 |
JPH1112175A (ja) * | 1997-06-27 | 1999-01-19 | Nisshin Flour Milling Co Ltd | 白血病治療剤 |
JP2000506489A (ja) * | 1995-07-17 | 2000-05-30 | センタ インタナショナル ドゥ リシェルシェ デルマトロジーク セ イ エール デ ガルデルマ | Ahpnを用いる癌の治療方法 |
JP2004528316A (ja) * | 2001-03-22 | 2004-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | 癌治療のための、レチノイド受容体リガンドおよび選択される細胞毒性剤の相乗的な組み合わせ |
WO2004093856A2 (en) * | 2003-04-16 | 2004-11-04 | Pharmacia Corporation | Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
WO2005027842A2 (en) * | 2003-09-18 | 2005-03-31 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
WO2005039490A2 (en) * | 2003-10-16 | 2005-05-06 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
JP2005512961A (ja) * | 2001-09-18 | 2005-05-12 | ゲー・ツヴァイ・エム キャンサー ドラッグス アー・ゲー | ヒト癌の組合せ療法的処置、及び腫瘍転移並びに微小残存病変処置のためのバルプロ酸及びその誘導体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8910069D0 (en) * | 1989-05-03 | 1989-06-21 | Janssen Pharmaceutica Nv | Method of topically treating acne vulgaris |
US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
US6624154B1 (en) * | 1999-04-23 | 2003-09-23 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
WO2002032413A2 (en) * | 2000-10-17 | 2002-04-25 | Board Of Regents, The University Of Texas System | A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes |
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
US20040209924A1 (en) * | 2001-09-26 | 2004-10-21 | Barry Hart | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
-
2007
- 2007-02-22 WO PCT/JP2007/053326 patent/WO2007108272A1/ja active Application Filing
- 2007-02-22 EP EP11184021A patent/EP2404596A1/en not_active Withdrawn
- 2007-02-22 ES ES07737319T patent/ES2395401T3/es active Active
- 2007-02-22 JP JP2008506203A patent/JP5113038B2/ja active Active
- 2007-02-22 US US12/293,912 patent/US20090117203A1/en not_active Abandoned
- 2007-02-22 EP EP07737319A patent/EP2005954B8/en active Active
-
2012
- 2012-07-12 US US13/547,758 patent/US20120277295A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07215882A (ja) * | 1993-09-22 | 1995-08-15 | Univ Leland Stanford Jr | 腫瘍の治療方法 |
JP2000506489A (ja) * | 1995-07-17 | 2000-05-30 | センタ インタナショナル ドゥ リシェルシェ デルマトロジーク セ イ エール デ ガルデルマ | Ahpnを用いる癌の治療方法 |
JPH1112175A (ja) * | 1997-06-27 | 1999-01-19 | Nisshin Flour Milling Co Ltd | 白血病治療剤 |
JP2004528316A (ja) * | 2001-03-22 | 2004-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | 癌治療のための、レチノイド受容体リガンドおよび選択される細胞毒性剤の相乗的な組み合わせ |
JP2005512961A (ja) * | 2001-09-18 | 2005-05-12 | ゲー・ツヴァイ・エム キャンサー ドラッグス アー・ゲー | ヒト癌の組合せ療法的処置、及び腫瘍転移並びに微小残存病変処置のためのバルプロ酸及びその誘導体 |
WO2004093856A2 (en) * | 2003-04-16 | 2004-11-04 | Pharmacia Corporation | Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
WO2005027842A2 (en) * | 2003-09-18 | 2005-03-31 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
WO2005039490A2 (en) * | 2003-10-16 | 2005-05-06 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
Non-Patent Citations (15)
Title |
---|
EMI N.: "Kyusei Zen Kotsudui Kyusei Hakketsubyo ni Taisuru Shinki Chiryoho", BESSATSU IGAKU NO AYUMI, 15 September 2005 (2005-09-15), pages 446 - 448, XP003017982 * |
FORMELLI F. ET AL.: "Synthetic retinoid Fenretinide is effective against a human ovarian carcinoma xenograft and potentiates Cisplatin activity", CANCER RESEARCH, vol. 53, no. 22, 15 November 1993 (1993-11-15), pages 5374 - 5376, XP008130036 * |
GANSLMAYER; MARION ET AL.: "showed the effects of 9-cis retinoic acid and tamoxifen for treatment of hepatocellular cells which was shown to be effective only in high concentration", JOURNAL OF HEPATOLOGY, vol. 40, no. 6, June 2004 (2004-06-01), pages 952 - 956 |
J. MA ET AL.: "provided a clinical study of combining arsenic trioxide, all-trans retinoic acid and idarubicin for induction therapy on patients with relapsed acute promyelocytic leukemia", EUROPEAN JOURNAL OF CANCER SUPPLEMENT, HERGOMEN, OXFORD GB, vol. 3, no. 2, 1 October 2005 (2005-10-01), pages 284 |
KAGECHIKA H.: "Gosei Tetinoids to sonorRinsho Oyo (Synthetic tetionoids and their clinical applications)", HEMATOLOGY & ONCOLOGY, vol. 51, no. 3, 28 September 2005 (2005-09-28), pages 277 - 282, XP003017987 * |
KALEMKERIAN G.P. ET AL.: "Activity of Fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines", CANCER CHEMOTHER. PHARMACOL., vol. 43, no. 2, February 1999 (1999-02-01), pages 145 - 150, XP002950455 * |
KAWAKITA T. ET AL.: "Kyusei Zen Kotsudui Kyusei Hakketsubyo Chiryo no Saikin no Hatten (Recent advances in the treatment of acute promyclocytic leukemia)", BIO CHIMICA, vol. 20, no. 13, 10 December 2005 (2005-12-10), pages 1153 - 1158, XP003017985 * |
KUROKI T. ET AL.: "Koganzei no Sayo Kiko", IWANAMI KOZA GENDAI IGAKU NO KISO 10 DAI 7 KAI HAIHON SAIBO ZOSHOKU TO GAN, KABUSHIKI KAISHA IWANAMI SHOTEN, 29 June 1999 (1999-06-29), pages 199 - 212, XP003017988 * |
LEUKEMIA RESEARCH, vol. 21, no. 1, 1997, pages 81 - 84 |
NANRI T. ET AL.: "Kyusei Zen Kotsuduisei Hakketsubyo (Actepromyelocytic leukemia)", HEMATOLOGY & ONCOLOGY, vol. 52, no. 1, 28 January 2006 (2006-01-28), pages 10 - 19, XP003017984 * |
SAHARA N. ET AL.: "Am-80, A Hissan ni yoru Kyusei Zen Kotsudui Kyusei Hakketsubyo no Chiryo", RINSHOI, vol. 31, no. 12, 10 December 2005 (2005-12-10), pages 1920 - 1923, XP003017983 * |
See also references of EP2005954A4 * |
SHUDO K. ET AL.: "kan Shuyo Chiroyozai toshite no Gosei Retinoid Kaihatsu-TAK-101 no Kiso to Rinsho eno Tenbo (Synthetic retinoid development as hepatic tumor therapeutic agent. Basis of TAC-101 and prospect of its clinical application)", THE JOURNAL OF CLINICAL SCIENCE, vol. 33, no. 6, June 1997 (1997-06-01), pages 721 - 727, XP003017990 * |
TALLMAN M.S. ET AL.: "Retinoids in Cancer Treatment", J. CLIN. PHARMACOL., vol. 32, no. 10, October 1992 (1992-10-01), pages 868 - 888, XP001000254 * |
YANADA M. ET AL.: "<<Hyojunteki Chiryoho to sono Mondaiten>>, Kyusei Zen Kotsuduikyusei Hakketsubyo", NAIKA, vol. 92, no. 3, 1 September 2003 (2003-09-01), pages 464 - 469, XP003017986 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015178426A1 (ja) * | 2014-05-21 | 2015-11-26 | 国立研究開発法人産業技術総合研究所 | がん幹細胞の増殖抑制剤 |
JPWO2015178426A1 (ja) * | 2014-05-21 | 2017-04-20 | 国立研究開発法人産業技術総合研究所 | がん幹細胞の増殖抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2005954A4 (en) | 2009-08-05 |
EP2404596A1 (en) | 2012-01-11 |
EP2005954A2 (en) | 2008-12-24 |
EP2005954B8 (en) | 2012-11-28 |
JPWO2007108272A1 (ja) | 2009-08-06 |
JP5113038B2 (ja) | 2013-01-09 |
EP2005954A9 (en) | 2009-07-15 |
ES2395401T3 (es) | 2013-02-12 |
EP2005954B1 (en) | 2012-10-24 |
US20120277295A1 (en) | 2012-11-01 |
US20090117203A1 (en) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007108272A1 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
RU2767664C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
PT2127652E (pt) | Agente libertador da hormona estimuladora dos folículos | |
JP2001509164A (ja) | 化学療法剤およびベンゾイミダゾールおよび任意にポテンシエーターを含む癌の成長を阻害するためのキット | |
TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
KR20100054210A (ko) | 암 치료를 위한 육산화사비소의 병용요법 | |
JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
JP2011514356A5 (ja) | ||
WO2016014390A1 (en) | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer | |
ES2896051T3 (es) | Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral | |
US20100266565A1 (en) | Combinational Chemotherapy Treatment | |
US20170087120A1 (en) | Composition for improving bioavailbility and efficacy of taxane | |
JP2004026811A (ja) | ビタミンd3誘導体を含有する抗癌作用を増強させるための薬剤 | |
TW202317128A (zh) | 治療化療相關的胃腸道副作用的化合物和方法 | |
JP2006527753A (ja) | 結腸直腸癌などの治療のための、血管損傷効果を有する、5−fu、cpt−11または5−fuおよびcpt−11と組み合わせたzd6126を含んでなる組成物 | |
Beggs et al. | Leukopenia Associated with Long-Term Colchicine Adminsitration | |
Kiba | Various toxicities: 2 case reports | |
TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林(ombrabulin)及順鉑(cisplatin)之抗腫瘤組合 | |
EP3265086A1 (en) | A lysosomal inhibitor and a multikinase inhibitor in the treatment of liver cancer | |
WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
JPWO2021173723A5 (ja) | ||
JP2012511554A (ja) | Ave8062およびドセタキセルを組み合わせる抗腫瘍組み合わせ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07737319 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008506203 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12293912 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007737319 Country of ref document: EP |